Rare.Monitor gives your commercial team one place to find new prospects, manage accounts, and track what's working, across over 160,000 UK and Ireland healthcare providers. Live market data and account management built into the same workflow, so your reps act on insight the moment they see it.
Three things commercial teams notice within the first month
01
Not a generic CRM and not a market-research subscription. Rare.Monitor is built around how pharma and medical device commercial teams actually work: targeting accounts, prioritising opportunities, and reading the channel they sell into.
02
The healthcare provider dataset behind Rare.Monitor is updated daily, not annually. Account lists, segmentation, and territory plans reflect what the market looks like now, not what it looked like when the last report went to press.
03
Prospecting, account management, market intelligence, and KOL mapping in a single platform. Insight stops getting lost between systems, and your commercial plan stays on one canvas.
Latest
Botulinum toxin is the most popular treatment offered by UK medical aesthetics clinics, with 86% of locations offering it. Other injectables, including dermal fillers (71%) and skin boosters (56%), are also offered by the majority of locations. A snapshot of the UK private medical aesthetics treatment landscape, April 2026.
30 April 2026
There are around 34,000 non-surgical aesthetics providers in the UK, of which 73% are HCP-led clinics and only 36% are formally registered with a healthcare regulator. A snapshot of the UK non-surgical aesthetics market from Rare.Monitor data, April 2026.
29 April 2026
Obagi accounts for 22.2% of all medical-grade skincare brand mentions across UK aesthetic clinics, and the top four brands hold 56% of detected mentions. This report breaks down share of brand mentions across eighteen brands tracked by Rare.Monitor in April 2026.
24 April 2026
